Shots:

• The companies launched Abevmy (biosimilar bevacizumab) referencing Avastin for the treatment of multiple types of cancer in Canada. Abevmy is the third oncology biosimilar & has been co-developed by Viatris and Biocon Biologics
• Abevmy is available to patients in the form of 100mg/4 mL single-use vials and 400mg/4 mL single-use vials. The companies have launched Viatris Advocate program that enables patients to access Abevmy & provides support and resources for patients, caregivers, and healthcare providers
• Under the Feb 2022 agreement with Viatris, Biocon Biologics will acquire Viatris' biosimilars portfolio globally, including Abevmy for ~$3.3B. The. The transaction is expected to close in H2’22

Ref:  Viatris | Image: Viatris